Courtagen to Provide Genetic Profiling for Raptor's Mitochondrial Disorder Drug Trial | GenomeWeb

NEW YORK (GenomeWeb News) — Courtagen Life Sciences said today that it has signed an agreement with Raptor Pharmaceuticals to provide genetic testing in the clinical trial for Raptor's RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders.

Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.